Company intelligence / Profile preview

Procuritas Capital Investors

Stockholm, Sweden

Ownership: Private
Development stage: Other

Overview

Procuritas is a Nordic mid‑market private equity firm, not an operating life science or biotech company, and therefore does not have its own therapeutic pipeline or clinical results.

Industry: Investors

Partnerships

Medpro/Omtanken (Medtanken primary care platform): Procuritas Capital Investors VI partnered with Medpro and Omtanken to build a new Swedish primary care group, later expanded via HMC, creating a large regional primary care platform.Precision BioLogic / Affinity Biologicals: Procuritas Capital Investors VII acquired Precision BioLogic and its subsidiary Affinity Biologicals, niche leaders in hemostasis diagnostics and research.

Beyond the preview

Go deeper on Procuritas Capital Investors.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Procuritas Capital Investors.

Explore the full profile